Cargando…

Clinical Management of Blood–Brain Barrier Disruptions after Active Raster-Scanned Carbon Ion Re-Radiotherapy in Patients with Recurrent Head-and-Neck Cancer

Purpose: The aim of the current evaluation was to assess central nervous system necrosis (CNSN) after re-irradiation with carbon ions (CR) in two-hundred seventeen (n = 217) patients with recurrent head-and-neck cancer (HNC). Methods: Thirty-six (n = 36) patients with CNSN were assessed retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Held, Thomas, Akbaba, Sati, Lang, Kristin, Harrabi, Semi, Bernhardt, Denise, Freudlsperger, Christian, Kargus, Steffen, Plinkert, Peter, Rieken, Stefan, Herfarth, Klaus, Debus, Jürgen, Adeberg, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469035/
https://www.ncbi.nlm.nih.gov/pubmed/30893824
http://dx.doi.org/10.3390/cancers11030383
_version_ 1783411560644870144
author Held, Thomas
Akbaba, Sati
Lang, Kristin
Harrabi, Semi
Bernhardt, Denise
Freudlsperger, Christian
Kargus, Steffen
Plinkert, Peter
Rieken, Stefan
Herfarth, Klaus
Debus, Jürgen
Adeberg, Sebastian
author_facet Held, Thomas
Akbaba, Sati
Lang, Kristin
Harrabi, Semi
Bernhardt, Denise
Freudlsperger, Christian
Kargus, Steffen
Plinkert, Peter
Rieken, Stefan
Herfarth, Klaus
Debus, Jürgen
Adeberg, Sebastian
author_sort Held, Thomas
collection PubMed
description Purpose: The aim of the current evaluation was to assess central nervous system necrosis (CNSN) after re-irradiation with carbon ions (CR) in two-hundred seventeen (n = 217) patients with recurrent head-and-neck cancer (HNC). Methods: Thirty-six (n = 36) patients with CNSN were assessed retrospectively regarding clinical symptoms and radiographic response. Results: CNSN were classified according to clinical management in line with the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. At a median follow-up of 25.3 months (range 3.3–79.9 months), the median time interval until occurrence of grade I, II, and III CNSN was 9.2 months (range 2.8–75.0 months), 10.2 months (range 2.3–60.5 months), and 16.6 months (range 8.7–32.5 months), respectively. In one patient with an adenocarcinoma infiltrating the frontal lobe, an extensive CNSN grade IV was suspected but the patient declined surgical intervention. Radiographic response after treatment of CNSN grade I, II, and III, defined as ≥25% reduction of the T2 alteration on Magnetic Resonance Imaging (MRI), was observed in 4 (16.0%), 5 (29.4%), and 4 (80%) patients, respectively. Conclusion: CNSN occurred late and frequent after re-irradiation with carbon ions in patients with HNC infiltrating the base of skull. The clinical outcome with adequate treatment was encouraging but correct diagnosis of CNSN remains challenging.
format Online
Article
Text
id pubmed-6469035
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64690352019-04-23 Clinical Management of Blood–Brain Barrier Disruptions after Active Raster-Scanned Carbon Ion Re-Radiotherapy in Patients with Recurrent Head-and-Neck Cancer Held, Thomas Akbaba, Sati Lang, Kristin Harrabi, Semi Bernhardt, Denise Freudlsperger, Christian Kargus, Steffen Plinkert, Peter Rieken, Stefan Herfarth, Klaus Debus, Jürgen Adeberg, Sebastian Cancers (Basel) Article Purpose: The aim of the current evaluation was to assess central nervous system necrosis (CNSN) after re-irradiation with carbon ions (CR) in two-hundred seventeen (n = 217) patients with recurrent head-and-neck cancer (HNC). Methods: Thirty-six (n = 36) patients with CNSN were assessed retrospectively regarding clinical symptoms and radiographic response. Results: CNSN were classified according to clinical management in line with the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. At a median follow-up of 25.3 months (range 3.3–79.9 months), the median time interval until occurrence of grade I, II, and III CNSN was 9.2 months (range 2.8–75.0 months), 10.2 months (range 2.3–60.5 months), and 16.6 months (range 8.7–32.5 months), respectively. In one patient with an adenocarcinoma infiltrating the frontal lobe, an extensive CNSN grade IV was suspected but the patient declined surgical intervention. Radiographic response after treatment of CNSN grade I, II, and III, defined as ≥25% reduction of the T2 alteration on Magnetic Resonance Imaging (MRI), was observed in 4 (16.0%), 5 (29.4%), and 4 (80%) patients, respectively. Conclusion: CNSN occurred late and frequent after re-irradiation with carbon ions in patients with HNC infiltrating the base of skull. The clinical outcome with adequate treatment was encouraging but correct diagnosis of CNSN remains challenging. MDPI 2019-03-19 /pmc/articles/PMC6469035/ /pubmed/30893824 http://dx.doi.org/10.3390/cancers11030383 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Held, Thomas
Akbaba, Sati
Lang, Kristin
Harrabi, Semi
Bernhardt, Denise
Freudlsperger, Christian
Kargus, Steffen
Plinkert, Peter
Rieken, Stefan
Herfarth, Klaus
Debus, Jürgen
Adeberg, Sebastian
Clinical Management of Blood–Brain Barrier Disruptions after Active Raster-Scanned Carbon Ion Re-Radiotherapy in Patients with Recurrent Head-and-Neck Cancer
title Clinical Management of Blood–Brain Barrier Disruptions after Active Raster-Scanned Carbon Ion Re-Radiotherapy in Patients with Recurrent Head-and-Neck Cancer
title_full Clinical Management of Blood–Brain Barrier Disruptions after Active Raster-Scanned Carbon Ion Re-Radiotherapy in Patients with Recurrent Head-and-Neck Cancer
title_fullStr Clinical Management of Blood–Brain Barrier Disruptions after Active Raster-Scanned Carbon Ion Re-Radiotherapy in Patients with Recurrent Head-and-Neck Cancer
title_full_unstemmed Clinical Management of Blood–Brain Barrier Disruptions after Active Raster-Scanned Carbon Ion Re-Radiotherapy in Patients with Recurrent Head-and-Neck Cancer
title_short Clinical Management of Blood–Brain Barrier Disruptions after Active Raster-Scanned Carbon Ion Re-Radiotherapy in Patients with Recurrent Head-and-Neck Cancer
title_sort clinical management of blood–brain barrier disruptions after active raster-scanned carbon ion re-radiotherapy in patients with recurrent head-and-neck cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469035/
https://www.ncbi.nlm.nih.gov/pubmed/30893824
http://dx.doi.org/10.3390/cancers11030383
work_keys_str_mv AT heldthomas clinicalmanagementofbloodbrainbarrierdisruptionsafteractiverasterscannedcarbonionreradiotherapyinpatientswithrecurrentheadandneckcancer
AT akbabasati clinicalmanagementofbloodbrainbarrierdisruptionsafteractiverasterscannedcarbonionreradiotherapyinpatientswithrecurrentheadandneckcancer
AT langkristin clinicalmanagementofbloodbrainbarrierdisruptionsafteractiverasterscannedcarbonionreradiotherapyinpatientswithrecurrentheadandneckcancer
AT harrabisemi clinicalmanagementofbloodbrainbarrierdisruptionsafteractiverasterscannedcarbonionreradiotherapyinpatientswithrecurrentheadandneckcancer
AT bernhardtdenise clinicalmanagementofbloodbrainbarrierdisruptionsafteractiverasterscannedcarbonionreradiotherapyinpatientswithrecurrentheadandneckcancer
AT freudlspergerchristian clinicalmanagementofbloodbrainbarrierdisruptionsafteractiverasterscannedcarbonionreradiotherapyinpatientswithrecurrentheadandneckcancer
AT kargussteffen clinicalmanagementofbloodbrainbarrierdisruptionsafteractiverasterscannedcarbonionreradiotherapyinpatientswithrecurrentheadandneckcancer
AT plinkertpeter clinicalmanagementofbloodbrainbarrierdisruptionsafteractiverasterscannedcarbonionreradiotherapyinpatientswithrecurrentheadandneckcancer
AT riekenstefan clinicalmanagementofbloodbrainbarrierdisruptionsafteractiverasterscannedcarbonionreradiotherapyinpatientswithrecurrentheadandneckcancer
AT herfarthklaus clinicalmanagementofbloodbrainbarrierdisruptionsafteractiverasterscannedcarbonionreradiotherapyinpatientswithrecurrentheadandneckcancer
AT debusjurgen clinicalmanagementofbloodbrainbarrierdisruptionsafteractiverasterscannedcarbonionreradiotherapyinpatientswithrecurrentheadandneckcancer
AT adebergsebastian clinicalmanagementofbloodbrainbarrierdisruptionsafteractiverasterscannedcarbonionreradiotherapyinpatientswithrecurrentheadandneckcancer